Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Pilot Study of Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

NCT05696782 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT05696782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05696782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Pilot Study of Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 2
Overall status
Recruiting
Start date
July 26, 2023
Completion date
April 30, 2027
Enrollment
28 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nonsmall cell lung cancer stage iii, nonsmall cell lung cancer, stage ii, unresectable non-small cell lung carcinoma